Lupin Share Price in Focus: Announced Acquisition of Huminsulin®

On December 30, 2024, Lupin Limited announced the acquisition of Huminsulin® in India from Eli Lilly and Company (Lilly) to further enhance its diabetes treatment portfolio. Lupin has previously marketed the Huminsulin range of products—comprising Insulin Human, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70—through existing Distribution and Promotion Agreements with Lilly in India. Following this announcement, Lupin share price rose by over 1%, reaching a high of ₹2,342.90, after opening at ₹2,309.65.

Huminsulin® Product Range for Diabetes Treatment

The Huminsulin range is indicated for the treatment of type 1 and type 2 diabetes mellitus, aiming to improve blood sugar control in both adults and children. Insulin treatment is the cornerstone of type 1 diabetes management and is often required in type 2 diabetes as the disease progresses. With a significant population in India affected by both types of diabetes, Insulin Human is commonly prescribed in combination with other therapies for effective disease management.

Lupin Leadership Comments

“This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide high-quality, affordable health care to our patients. It reinforces our unwavering commitment to combating diabetes and providing comprehensive care,” said Nilesh Gupta, Managing Director, Lupin.

Commenting on the acquisition, Rajeev Sibal, President – India Region Formulations, Lupin said, “Lupin has been at the forefront of providing holistic diabetes care to patients. This acquisition further strengthens our diabetes portfolio and enables us to offer a broad range of human insulin options to millions of patients, thereby helping them lead healthier lives.”

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in securities market are subject to market risks, read all the related documents carefully before investing.